Exact Mass: 463.314501
Exact Mass Matches: 463.314501
Found 231 metabolites which its exact mass value is equals to given mass value 463.314501,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Gentamicin C2
C20H41N5O7 (463.30058360000004)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
Sagamicin
Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
gentamicin C2a
C20H41N5O7 (463.30058360000004)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
Bilastine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Bilastine is a second-generation piperidine H1-antihistamine. Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria.
LysoPE(P-18:1(9Z)/0:0)
C23H46NO6P (463.30625860000004)
LysoPE(P-18:1(9Z)/0:0) is a phospho-ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin and choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
3-Hydroxyarachidonoylcarnitine
C27H45NO5 (463.32975600000003)
3-Hydroxyarachidonoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,14Z)-hydroxyicosa-5,8,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyarachidonoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyarachidonoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8S,9E,11Z,14Z)-8-Hydroxyicosa-5,9,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5E,7Z,11Z,14Z)-9-Hydroxyicosa-5,7,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,11Z,14Z)-3-hydroxyicosa-5,8,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(10E)-11-(3,4-Dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine
C27H45NO5 (463.32975600000003)
(10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-{3,4-Dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine
C27H45NO5 (463.32975600000003)
11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-Oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylalanine
C27H45NO5 (463.32975600000003)
Chenodeoxycholylalanine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylalanine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Alanine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylalanine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylalanine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylalanine
C27H45NO5 (463.32975600000003)
Deoxycholylalanine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylalanine consists of the bile acid deoxycholic acid conjugated to the amino acid Alanine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylalanine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylalanine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Bucromarone
C29H37NO4 (463.27224420000005)
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
Gentamicin C2
C20H41N5O7 (463.30058360000004)
GLP-1 antagonist
Micronomicin
C20H41N5O7 (463.30058360000004)
Peregrine
C26H41NO6 (463.29337260000005)
Phosphatidylethanolamine lyso alkenyl 18:1
C23H46NO6P (463.30625860000004)
(13E,21E)-(7S,16R)-6,7-epoxy-16-methyl-10-phenyl-[14]cytochalasa-13,21-diene-1,23-dione
C29H37NO4 (463.27224420000005)
(13E,21E)-(7S,16R,20R)-7,20-dihydroxy-16-methyl-10-phenyl-[14]-cytochalasa-5,13,21-triene-1,23-dione
C29H37NO4 (463.27224420000005)
Peimisine HCl
C27H42ClNO3 (463.28530520000004)
Alanine conjugated chenodeoxycholic acid
C27H45NO5 (463.32975600000003)
3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid
C27H45NO5 (463.32975600000003)
N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine
C27H45NO5 (463.32975600000003)
N-((4R)-4-((3R,5S,7S,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine
C27H45NO5 (463.32975600000003)
((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine
C26H41NO6 (463.29337260000005)
Ala Phe Lys Val
C23H37N5O5 (463.27945520000003)
Ala Phe Val Lys
C23H37N5O5 (463.27945520000003)
Ala Lys Phe Val
C23H37N5O5 (463.27945520000003)
Ala Lys Val Phe
C23H37N5O5 (463.27945520000003)
Ala Val Phe Lys
C23H37N5O5 (463.27945520000003)
Ala Val Lys Phe
C23H37N5O5 (463.27945520000003)
Phe Ala Lys Val
C23H37N5O5 (463.27945520000003)
Phe Ala Val Lys
C23H37N5O5 (463.27945520000003)
Phe Gly Ile Lys
C23H37N5O5 (463.27945520000003)
Phe Gly Lys Ile
C23H37N5O5 (463.27945520000003)
Phe Gly Lys Leu
C23H37N5O5 (463.27945520000003)
Phe Gly Leu Lys
C23H37N5O5 (463.27945520000003)
Phe Ile Gly Lys
C23H37N5O5 (463.27945520000003)
Phe Ile Lys Gly
C23H37N5O5 (463.27945520000003)
Phe Lys Ala Val
C23H37N5O5 (463.27945520000003)
Phe Lys Gly Ile
C23H37N5O5 (463.27945520000003)
Phe Lys Gly Leu
C23H37N5O5 (463.27945520000003)
Phe Lys Ile Gly
C23H37N5O5 (463.27945520000003)
Phe Lys Leu Gly
C23H37N5O5 (463.27945520000003)
Phe Lys Val Ala
C23H37N5O5 (463.27945520000003)
Phe Leu Gly Lys
C23H37N5O5 (463.27945520000003)
Phe Leu Lys Gly
C23H37N5O5 (463.27945520000003)
Phe Val Ala Lys
C23H37N5O5 (463.27945520000003)
Phe Val Lys Ala
C23H37N5O5 (463.27945520000003)
Gly Phe Ile Lys
C23H37N5O5 (463.27945520000003)
Gly Phe Lys Ile
C23H37N5O5 (463.27945520000003)
Gly Phe Lys Leu
C23H37N5O5 (463.27945520000003)
Gly Phe Leu Lys
C23H37N5O5 (463.27945520000003)
Gly Ile Phe Lys
C23H37N5O5 (463.27945520000003)
Gly Ile Lys Phe
C23H37N5O5 (463.27945520000003)
Gly Lys Phe Ile
C23H37N5O5 (463.27945520000003)
Gly Lys Phe Leu
C23H37N5O5 (463.27945520000003)
Gly Lys Ile Phe
C23H37N5O5 (463.27945520000003)
Gly Lys Leu Phe
C23H37N5O5 (463.27945520000003)
Gly Leu Phe Lys
C23H37N5O5 (463.27945520000003)
Gly Leu Lys Phe
C23H37N5O5 (463.27945520000003)
Ile Phe Gly Lys
C23H37N5O5 (463.27945520000003)
Ile Phe Lys Gly
C23H37N5O5 (463.27945520000003)
Ile Gly Phe Lys
C23H37N5O5 (463.27945520000003)
Ile Gly Lys Phe
C23H37N5O5 (463.27945520000003)
Ile Lys Phe Gly
C23H37N5O5 (463.27945520000003)
Ile Lys Gly Phe
C23H37N5O5 (463.27945520000003)
Lys Ala Phe Val
C23H37N5O5 (463.27945520000003)
Lys Ala Val Phe
C23H37N5O5 (463.27945520000003)
Lys Phe Ala Val
C23H37N5O5 (463.27945520000003)
Lys Phe Gly Ile
C23H37N5O5 (463.27945520000003)
Lys Phe Gly Leu
C23H37N5O5 (463.27945520000003)
Lys Phe Ile Gly
C23H37N5O5 (463.27945520000003)
Lys Phe Leu Gly
C23H37N5O5 (463.27945520000003)
Lys Phe Val Ala
C23H37N5O5 (463.27945520000003)
Lys Gly Phe Ile
C23H37N5O5 (463.27945520000003)
Lys Gly Phe Leu
C23H37N5O5 (463.27945520000003)
Lys Gly Ile Phe
C23H37N5O5 (463.27945520000003)
Lys Gly Leu Phe
C23H37N5O5 (463.27945520000003)
Lys Ile Phe Gly
C23H37N5O5 (463.27945520000003)
Lys Ile Gly Phe
C23H37N5O5 (463.27945520000003)
Lys Leu Phe Gly
C23H37N5O5 (463.27945520000003)
Lys Leu Gly Phe
C23H37N5O5 (463.27945520000003)
Lys Val Ala Phe
C23H37N5O5 (463.27945520000003)
Lys Val Phe Ala
C23H37N5O5 (463.27945520000003)
Leu Phe Gly Lys
C23H37N5O5 (463.27945520000003)
Leu Phe Lys Gly
C23H37N5O5 (463.27945520000003)
Leu Gly Phe Lys
C23H37N5O5 (463.27945520000003)
Leu Gly Lys Phe
C23H37N5O5 (463.27945520000003)
Leu Lys Phe Gly
C23H37N5O5 (463.27945520000003)
Leu Lys Gly Phe
C23H37N5O5 (463.27945520000003)
Val Ala Phe Lys
C23H37N5O5 (463.27945520000003)
Val Ala Lys Phe
C23H37N5O5 (463.27945520000003)
Val Phe Ala Lys
C23H37N5O5 (463.27945520000003)
Val Phe Lys Ala
C23H37N5O5 (463.27945520000003)
Val Lys Ala Phe
C23H37N5O5 (463.27945520000003)
Val Lys Phe Ala
C23H37N5O5 (463.27945520000003)
PA(19:3/0:0)
C22H42NO7P (463.26987520000006)
PE(17:2(9Z,12Z)/0:0)
C22H42NO7P (463.26987520000006)
CAR 20:4;O
C27H45NO5 (463.32975600000003)
AQ-RA 741
tert-butyl 2-[2-[(2-amino-2-cyclohexylacetyl)amino]-3,3-dimethylbutanoyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxylate
C26H45N3O4 (463.34098900000004)
(3β,5α,6α,16β)-Cevane-3,6,14,16,20-pentol
C27H45NO5 (463.32975600000003)
Sarcoursodeoxycholic acid
C27H45NO5 (463.32975600000003)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
bilastine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria.
Bucromarone
C29H37NO4 (463.27224420000005)
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5E,7Z,11Z,14Z)-9-Hydroxyicosa-5,7,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8S,9E,11Z,14Z)-8-Hydroxyicosa-5,9,11,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoylcarnitine
C27H45NO5 (463.32975600000003)
(10E)-11-(3,4-Dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine
C27H45NO5 (463.32975600000003)
11-{3,4-Dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine
C27H45NO5 (463.32975600000003)
(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-Oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine
C27H45NO5 (463.32975600000003)
beta-D-galactosyl-(1<->1)-sphinganine
C24H49NO7 (463.35088440000004)
3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-6-ethyl-1H-quinolin-2-one
3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-5,7-dimethyl-1H-quinolin-2-one
N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine
C27H45NO5 (463.32975600000003)
(1R,2S,3R,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-ribo-heptopyranoside
C20H41N5O7 (463.30058360000004)
N-[(3alpha,5beta,12alpha)-3,12-dihydroxy-7,24-dioxocholan-24-yl]glycine
C26H41NO6 (463.29337260000005)
(2S,3R)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid
C27H45NO5 (463.32975600000003)
((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine
C26H41NO6 (463.29337260000005)
2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate
C23H46NO6P (463.30625860000004)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate
C22H42NO7P (463.26987520000006)
(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dec-4-ene-1-sulfonic acid
C23H45NO6S (463.29674300000005)
3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]undecane-1-sulfonic acid
C23H45NO6S (463.29674300000005)
3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]decane-1-sulfonic acid
C23H45NO6S (463.29674300000005)
(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)undec-4-ene-1-sulfonic acid
C23H45NO6S (463.29674300000005)
2-(Decanoylamino)-3-hydroxytetradecane-1-sulfonic acid
C24H49NO5S (463.3331264000001)
3-Hydroxy-2-(tridecanoylamino)undecane-1-sulfonic acid
C24H49NO5S (463.3331264000001)
2-(Dodecanoylamino)-3-hydroxydodecane-1-sulfonic acid
C24H49NO5S (463.3331264000001)
3-Hydroxy-2-(tetradecanoylamino)decane-1-sulfonic acid
C24H49NO5S (463.3331264000001)
3-Hydroxy-2-(undecanoylamino)tridecane-1-sulfonic acid
C24H49NO5S (463.3331264000001)
cis-5-(6-Carboxyhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine
(3S)-5beta-(6-Formylhexyl)-4alpha-[(E)-3-hydroxy-1-octenyl]-2,3alpha-diphenylisoxazolidine
2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-acetamido-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Micronomicin
Micronomicin is an antibiotic that belongs to the aminoglycoside class of organic compounds. Aminoglycosides are characterized by aminocyclitols linked to amino sugars, forming aminoglycoside antibiotics. These compounds are known for their broad-spectrum activity against various microorganisms, particularly bacteria. Micronomicin, specifically, features a structure where an aminocyclitol is connected to an amino sugar through a glycosidic bond. This structure is typical of aminoglycosides and contributes to their antimicrobial properties. The exact configuration and arrangement of atoms in micronomicin give it its specific antimicrobial profile. Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
3-hydroxyarachidonoylcarnitine
C27H45NO5 (463.32975600000003)
An O-acylcarnitine having 3-hydroxyarachidonoyl as the acyl substituent.
1-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine
C22H42NO7P (463.26987520000006)
lysophosphatidylcholine 14:2
C22H42NO7P (463.26987520000006)
A lysophosphatidylcholine in which the remaining acyl group contains 14 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
lysophosphatidylethanolamine P-18:1
C23H46NO6P (463.30625860000004)
A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group contains 18 carbons and has 1 additional double bond
Hex1SPH(18:0)
C24H49NO7 (463.35088440000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
NMI 8739
NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.
(1s,12r,14r,15r,16s,17s,20s)-14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate
16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C26H41NO6 (463.29337260000005)
(3s,3ar,4s,6s,6as,10r,14s,17ar)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)
1-[(4ar,5r,7r,8as)-5-{[(1r,9r,11s,13r,17s)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadeca-2,4,6-trien-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
(5r,9r,12ar,15s,15as,16s,18as)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
(5r,9r,12as,15s,15as,16s,18ar)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
14-acetyltalatizamine
C26H41NO6 (463.29337260000005)
{"Ingredient_id": "HBIN001359","Ingredient_name": "14-acetyltalatizamine","Alias": "NA","Ingredient_formula": "C26H41NO6","Ingredient_Smile": "NA","Ingredient_weight": "463.61","OB_score": "NA","CAS_id": "71239-55-9","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9321","PubChem_id": "NA","DrugBank_id": "NA"}
benzoylnapelline
C29H37NO4 (463.27224420000005)
{"Ingredient_id": "HBIN017824","Ingredient_name": "benzoylnapelline","Alias": "NA","Ingredient_formula": "C29H37NO4","Ingredient_Smile": "NA","Ingredient_weight": "463.61","OB_score": "34.05649896","CAS_id": "198126-85-1","SymMap_id": "SMIT04655","TCMID_id": "NA","TCMSP_id": "MOL002410","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16r,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO6 (463.29337260000005)
(9r,12as,15s,15as,16s,18ar)-18-hydroxy-16-[(4-hydroxyphenyl)methyl]-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
(2s)-2-{[(2r)-1-hydroxy-2-[(2s,3r)-2-[(1-hydroxyethylidene)amino]-n,3-dimethylpentanamido]-3-(4-hydroxyphenyl)propylidene]amino}-4-methylpentanoic acid
18-hydroxy-16-[(4-hydroxyphenyl)methyl]-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)
11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO6 (463.29337260000005)
(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO6 (463.29337260000005)
(3s,3ar,6s,6ar,10r,14r,17as)-3-benzyl-1,6,14-trihydroxy-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)
(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-4-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate
C26H41NO6 (463.29337260000005)
(1s,4e,10r,12e,14s,15s,17r,18s,19s,20s)-20-benzyl-22-hydroxy-10,17,18-trimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C29H37NO4 (463.27224420000005)
3-{[(1r,2s,4ar,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-2-hydroxy-5-{[2-(4-hydroxyphenyl)ethyl]amino}cyclohexa-2,5-diene-1,4-dione
C29H37NO4 (463.27224420000005)
(3s,3ar,4s,6s,6ar,10r,14r,17as)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)
20-benzyl-22-hydroxy-10,17,18-trimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C29H37NO4 (463.27224420000005)
(9s,12ar,13s,15as,16r,18ar)-16-benzyl-13,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,13h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-2-one
C29H37NO4 (463.27224420000005)
2-[(1-hydroxy-2-{2-[(1-hydroxyethylidene)amino]-n,3-dimethylpentanamido}-3-(4-hydroxyphenyl)propylidene)amino]-4-methylpentanoic acid
1-[5-({11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadeca-2,4,6-trien-5-yl}methyl)-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO6 (463.29337260000005)
(3s,4s,6s,10r,14r,17ar)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)
(1r,2s,3s,4s,5s,6r,8r,9r,10s,13r,16r,17s)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO6 (463.29337260000005)
14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate
1-[(4as,5r,7s,8ar)-5-{[(1s,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadeca-2,4,6-trien-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
3-benzyl-1,6,14-trihydroxy-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one
C29H37NO4 (463.27224420000005)